Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers despite Waning T-Cell Responses during Antiretroviral Therapy

Nikolaus Jilg, Pilar Garcia-Broncano, Michael Peluso, Florencia P. Segal, Ronald J. Bosch, Carla Roberts-Toler, Samantha M.Y. Chen, Cornelius N. Van Dam, Michael C. Keefer, Daniel R. Kuritzkes, Alan L. Landay, Steven Deeks, Xu G. Yu, Paul E. Sax, Jonathan Z. Li

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

AIDS Clinical Trials Group study A5308 found reduced T-cell activation and exhaustion in human immunodeficiency virus (HIV) controllers start antiretroviral therapy (ART). We further assessed HIV-specific T-cell responses and post-ART viral loads. Before ART, the 31% of participants with persistently undetectable viremia had more robust HIV-specific T-cell responses. During ART, significant decreases were observed in a broad range of T-cell responses. Eight controllers in A5308 and the Study of the Consequences of the Protease Inhibitor Era (SCOPE) cohort showed no viremia above the level of quantification in the first 12 weeks after ART discontinuation. ART significantly reduced HIV-specific T-cell responses in HIV controllers but did not adversely affect controller status after ART discontinuation.

Original languageEnglish (US)
Pages (from-to)1837-1842
Number of pages6
JournalJournal of Infectious Diseases
Volume222
Issue number11
DOIs
StatePublished - Dec 1 2020
Externally publishedYes

Keywords

  • antiretroviral therapy
  • elite controllers
  • HIV controllers
  • T-cell response
  • treatment interruption
  • viremic control

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers despite Waning T-Cell Responses during Antiretroviral Therapy'. Together they form a unique fingerprint.

Cite this